Langer, Christiane
University of Southern California · Merck & Co., Inc., Rahway, NJ, USA (United States) · Bristol-Myers Squibb (United States) · USC Norris Comprehensive Cancer Center
3 papers on CoChat
Most cited papers
- Verified
K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
Karapetis, C. S., Khambata-Ford, S., Jonker, D. J., O'Callaghan, C. J., Tu, D., Tebbutt, N. C., Simes, R. J., Chalchal, H., Shapiro, J. D., Robitaille, S., et al. (2008) · New England Journal of Medicine
Colorectal Cancer Treatments and StudiesColorectal Cancer Surgical Treatments
Cited by 3,622
- Verified
Cetuximab for the Treatment of Colorectal Cancer
Jonker, D. J., O'Callaghan, C. J., Karapetis, C. S., Zalcberg, J. R., Tu, D., Au, H.-J., Berry, S. R., Krahn, M., Price, T., Simes, R. J., et al. (2007) · New England Journal of Medicine
Colorectal Cancer Treatments and StudiesHER2/EGFR in Cancer Research
Cited by 1,904
- Verified
Germline Polymorphisms in Genes Involved in the IGF1 Pathway Predict Efficacy of Cetuximab in Wild-type KRAS mCRC Patients
Winder, T., Zhang, W., Yang, D., Ning, Y., Bohanes, P., Gerger, A., Wilson, P. M., Pohl, A., Mauro, D. J., Langer, C., et al. (2010) · Clinical Cancer Research
Colorectal Cancer Treatments and StudiesGenetic factors in colorectal cancer
Cited by 46
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free